IASLC Lung Cancer News (ILCN), March 2023
ILCN | English
Image For Activity Cover
Credit Offered
No Credit Offered
Table of Contents
  • Pragmatic Approach to Trial Design Born from Lung-MAP Substudy
  • New Texas Lung Cancer Conference Planned with Busy Clinicians in Mind
  • ILCN Editor Dr. Corey J. Langer Reflects on the ‘Fantastic Voyage’ From Nihilism to Hope in Thoracic Oncology
  • Specialists Debate the Merits of Lorlatinib as a Universal First-Line Treatment for ALK+ Patients
  • Study Explores First-Line Osimertinib for NSCLC Patients with Uncommon EGFR Mutations
  • Narrow Focus Allows Pragmatica-Lung Trial to Minimize Eligibility Criteria, Significantly Reduce Data Collection, Researcher Says
  • Tobacco Control Impacts Everyone in Respiratory Medicine, JTO CRR Editor Says
  • Patient Perspective: ‘Scanxiety’ Triggered by Cancer, Not Scans
  • TTLC Keynote Speaker Explores Progress, Potential Breakthroughs of SCLC Therapies
  • Experts Debate TKI Use After Disease Progression for Patients with EGFR Mutations
  • Scenes from TTLC 2023
IASLC Lung Cancer News (ILCN) is the offical news source of the only global association dedicated to the multidisciplinary study of lung cancer, published bimonthly by the International Association for the Study of Lung Cancer (IASLC). 

Click here to link to Submission Guidelines.
Powered By